Sheff DD Alert #3 on PDMI (.0021) could be a potential buyout from a big ophthalmology medical company as potential is discovered from their products.
"From the 312 bi-manual cases; 51 eyes were selected to perform a new technique using ultrasound emulsification & Laser Phacolysis (Bi-manual-Bi-Energy) simultaneously utilizing two systems: Paradigm's Photon System & Alcon's Legacy McCool or Accurus systems. "
"Conclusion...The Bi-manual-Bi-Energy (BIMBIE)technique can remove literally any kind of cataract through two small paracenthesis, using almost half the energy necessary compared to the traditional KPE techniques, and it is the key that connects the Kelman phacomulsification technique with the phacolysis technique."
This is a groundbreaking approach for surgical techniques and it is using the Alcon system & Paradigm system in combination. That is significant to any big medical company particularly Alcon. Great to see a small upstart like Paradigm mentioned in the same name as a company great like Alcon. Paradigm products have signficant value that big companies are starting to realize.
Per the PR, PMDI appointed a new President, Stephen Davis. He has an excellent track record in the Medical field.
"Mr. Davis brings over 25 years of experience in global healthcare and medical devices markets and over 14 of those in the ophthalmic arena to Paradigm Medical Industries, Inc. Stephen has also served as the President and CEO for Zinetics Medical, Inc. Salt Lake City, Utah for nine years. Stephen was successful in raising over $2.7 million for Zinetics Medical and spearheaded the purchase of Zinetics Medical by Medtronic for over $50 million. He served as Site Director for Medtronic Functional Diagnostics for a year after the conclusion of the sale of Zinetics Medical. Prior to those responsibilities, Stephen was the Western Area Director for Barnes-Hind Hydrocurve and held additional responsibilities as a Regional Vice-President and District Sales Manager. He possesses a stellar background in the areas of strategic planning, start-up ventures, P&L and has a successful record in developing business in preparation for acquisition. Mr. Davis also has an extensive knowledge of the International markets. Stephen has a B.S. from Brigham Young University and additional studies in International Business and Finance." He served as Site Director for Medtronic Functional Diagnostics for a year after the conclusion of the sale of Zinetics Medical. Prior to those responsibilities, Stephen was the Western Area Director for Barnes-Hind Hydrocurve and held additional responsibilities as a Regional Vice-President and District Sales Manager He possesses a stellar background in the areas of strategic planning, start-up ventures, P&L and has a successful record in developing business in preparation for acquisition.
What's special about that post is that ASFX actually was .0002 in June to later just recently hit .08 per share with a far greater share structure than what is here with PDMI. IMHO
As many of you already know, I am very familiar with ASFX. In just now finishing the IBox for PDMI, I can tell you that PDMI has far more potential and better products that are FDA approved than that of ASFX. Plus they have the patents. PDMI might be transforming into something special.
w/PDMI (.0045) Hit .0053 today! I alerted here w/ a DD Post and at the Sheff Station last Thursday at .0015. Has been a 250%% gain in only 3 days. These medical plays are flying. Real products, partnerships, and products. Glad people are doing well in this one! Best, $heff
Market Data 
Markets 
AI
